#	Pagina
attuale pagina	/open-h2020/projects/207923/index.html

Opendata, web and dolomites

AXONE SIGNED

Commercial multiple electrode lead technology for cardiac disease

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

AXONE project word cloud

Explore the words cloud of the AXONE project. It provides you a very rough idea of what is the project "AXONE" about.

25 commercial placed validation positive class sales manufacture confirm single projected efficiency spaced left plan 14 impressive chronic is4 million cardiac reducing 2020 device considerably axone leaving rate compete initiated heart previously advantages times place performance vary selling population decrease 70 acute implantation perform direct resynchronization therapy industrialization launch procedure leads market stimulate coronary time marketing finalise generates individual give responder pacing yearly 50 finalize definition combines medical pacemaker commercialization global dominated people prepare diameter marking ce start 2026 effect vein file sites capability site revenues 82 clinical crt healthcare patients companies smaller ventricle commercialisation depending generation benefits opportunity

Project "AXONE" data sheet

The following table provides information about the project.

Coordinator	SORIN CRM SAS Organization address address: AVENUE REAUMUR 4 city: CLAMART postcode: 92140 website: www.sorin-crm.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.crm.microport.com/
Total cost	3˙513˙187 €
EC max contribution	2˙694˙187 € (77%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2. (PRIORITY 'Industrial leadership')
Code Call	H2020-FTIPilot-2016-1
Funding Scheme	IA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2019-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SORIN CRM SAS SORIN CRM SAS Organization address address: AVENUE REAUMUR 4 city: CLAMART postcode: 92140 website: www.sorin-crm.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (CLAMART)	coordinator	1˙373˙312.00
2	HERAEUS DEUTSCHLAND GMBH & CO KG HERAEUS DEUTSCHLAND GMBH & CO KG Organization address address: HERAEUSSTRASSE 12-14 city: HANAU postcode: 63450 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANAU)	participant	537˙687.00
3	CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN Organization address address: RUE DE GERMONT 1 city: ROUEN postcode: 76031 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (ROUEN)	participant	425˙062.00
4	UNIVERSITEIT MAASTRICHT UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	358˙125.00

Map

Project objective

Heart failure affects more than 14 million people in Europe, and is projected to affect about 30 million people by 2020. While the effects of Cardiac Resynchronization Therapy on the wider heart failure population are impressive, benefits at the individual level vary considerably. Depending on the definition, the responder rate CRT is positive in 50-70% of patients, leaving 30-50% without any significant effect. This project will finalise the development of a pacemaker cardiac lead that is 5 times smaller diameter than the state-of-the-art, and start the commercialisation of the product. The project will directly improve the efficiency of Cardiac Resynchronization Therapy (CRT) by reducing the time required for the implantation procedure by 25%, and decrease the yearly healthcare costs by 82 M€/year in Europe. In addition, the project will help European companies to compete in the pacemaker market currently dominated by US companies. Axone IS4 lead combines the advantages of a single lead, which is easy to place in any coronary vein, with the capability to stimulate the left ventricle at 2 widely spaced sites for a more global resynchronization – this has previously required 2 leads to be placed in the heart. The objective of the AXONE project is to: • Finalize product industrialization. • Confirm chronic pre-clinical performance with large scale studies. • Perform an acute clinical study and a chronic clinical validation. • Manufacture clinical and commercial products. • Build the marketing plan and prepare the product launch. • File CE marking of the class III medical device system. • Launch the commercialization of AXONE system and start selling the system in Europe. This novel approach of multi-site pacing has the potential to become the next CRT therapy device generation, initiated in Europe. This project will give an opportunity to generates 90 M€ direct revenues sales in 2026.

Deliverables

List of deliverables.
Final acute clinical study report	Documents, reports	2019-05-31 10:02:15
AXONE benefit over standard CRT report	Documents, reports	2019-05-31 10:02:12
Preclinical safety performance report	Documents, reports	2019-05-31 10:02:12

Take a look to the deliverables list in detail: detailed list of AXONE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AXONE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AXONE" are provided by the European Opendata Portal: CORDIS opendata.